Strive, Inc. (ASST) Stock Price & Analysis
Strive, Inc. (ASST) closed at USD 29.03 on Thursday, October 22, 2026, down 5.59% on the day. The US market is currently closed (pre-market); this is not a live price.
The prior close was USD 30.75; the Oct 22, 2026 session ranged USD 27.96–29.77 on volume of 7,787,951 shares. Market capitalization is $2.93B, with a 52-week range of USD 7.02–36.2 (NGM). Source: Nexqual, retrieved October 23, 2026 at 09:16 UTC.
Also available as compact Markdown for AI agents: nexqual.com/ASST.md
Key facts (ASST)
- Last four reported quarters (through Jun 30, 2026): revenue $8.7M, net income -$926M (-10614.2% margin) (SEC filings).
- Insider open-market sales, last ~7 months: 6 Form 4 filings, $3.2M; 6 not under a Rule 10b5-1 plan ($3.2M); 0 by opportunistic insiders, 0 by routine insiders (three-year test, Cohen, Malloy & Pomorski 2012).
- Insider open-market purchases, last ~7 months: 1 Form 4 filing, $199K; 0 by opportunistic insiders, 0 by routine insiders.
- Analysts: Buy (mean 1.80 on a 1–5 scale) (5 analysts), mean target USD 38.8 (range 32–56).
- Total return with dividends: 1Y +68.0% vs S&P 500 +14.9%; 5Y -91.8% vs S&P 500 +80.3%.
- Next earnings: 2026-11-10, EPS estimate USD -0.22, revenue estimate $3.1M.
Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters) (ASST)
| USD | FY2021 | FY2022 | FY2023 | FY2024 | TTM |
|---|---|---|---|---|---|
| Revenue | $830K | $343K | $277K | $3.6M | $8.7M |
| Operating income | $15K | -$645K | -$4.9M | -$22.7M | -$816M |
| Net income | $15K | -$645K | -$4.9M | -$21.6M | -$926M |
| EPS (diluted) | $0.00 | -$6.00 | -$37.00 | -$9.75 | — |
| Free cash flow | — | — | -$3.8M | -$21.6M | — |
| Operating margin | 1.8% | -188.1% | -1780.0% | -620.7% | -9356.1% |
| Net margin | 1.8% | -188.1% | -1780.0% | -591.2% | -10614.2% |
| Revenue growth | — | -58.6% | -19.3% | +1217.5% | — |
| Cash + short-term investments | $34K | $137K | $2.9M | $6.2M | — |
Fiscal years end Dec. EPS is split-adjusted.
Valuation (price ÷ last four quarters, through Jun 30, 2026) (ASST)
P/S 335.9x · P/B 4.5x · Earnings yield -31.60%
Insider sales (SEC Form 4, open-market, last ~7 months) (ASST)
0 of 6 under a Rule 10b5-1 trading plan (scheduled in advance). Unplanned sales were timed by the insider.
| Trade date | Insider | Role | Shares | Value | % of holdings sold | 10b5-1 plan | Insider type |
|---|---|---|---|---|---|---|---|
| 2026-10-05 | Pham Benjamin | Chief Financial Officer | 4,209 | $132K | 19.5% | No | Too little history (no open-market trades in 2023–2025) |
| 2026-10-05 | Cole Matthew Ryan | Chief Executive Officer | 58,789 | $1.8M | 7.2% | No | Too little history (no open-market trades in 2023 or 2024) |
| 2026-10-05 | Macey Jonathan R | Director | 6,700 | $203K | 45.2% | No | Too little history (no open-market trades in 2023–2025) |
| 2026-10-05 | Lavish James | Director | 6,000 | $185K | 40.5% | No | Too little history (no open-market trades in 2023–2025) |
| 2026-10-05 | Beirne Brian Logan | Chief Legal Officer | 20,077 | $629K | 32.6% | No | Too little history (no open-market trades in 2023–2025) |
| 2026-10-05 | Sarkhani Arshia | Chief Marketing Officer | 5,634 | $177K | 32.3% | No | Too little history (no open-market trades in 2023 or 2025) |
% of holdings sold = shares sold ÷ (shares sold + all holdings the insider reported on that Form 4, direct and through trusts).
Insider type follows Cohen, Malloy & Pomorski (Journal of Finance, 2012). An insider who traded the stock in the same calendar month in each of the past three years is a routine trader; one who traded in each of those years without such a pattern is an opportunistic trader. In their study, trades by opportunistic insiders predicted future returns and trades by routine insiders did not. Counts open-market purchases and sales only (SEC Form 4 codes P and S) by that insider in that company. Not investment advice.
Insider purchases (SEC Form 4, open-market, last ~7 months) (ASST)
1 purchase, $199K. Private placements, offerings, dividend reinvestment and employee stock purchase plan buys are excluded.
| Trade date | Insider | Role | Shares | Value | Avg price | Insider type |
|---|---|---|---|---|---|---|
| 2026-08-14 | Rochard Pierre | Director | 15,900 | $199K | 12.54 | Too little history (no open-market trades in 2023–2025) |
Analysts (ASST)
Consensus Buy (mean 1.80 on a 1–5 scale), 5 analysts; mean target USD 38.8 (low 32, high 56).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-10-12 | Maxim Group | Target raised | Buy | $21 → $37 |
| 2026-09-22 | B. Riley Securities | Target raised | Buy | $26 → $33 |
| 2026-09-03 | B. Riley Securities | Target raised | Buy | $16 → $26 |
| 2026-08-11 | HC Wainwright & Co. | Target lowered | Buy | $37 → $36 |
| 2026-07-22 | TD Cowen | Target lowered | Buy | $32 → $28 |
Total return (dividends reinvested) (ASST)
| 1Y (from 2025-10-23) | 5Y (from 2023-01-30) | |
|---|---|---|
| Total return | +68.0% | -91.8% |
| S&P 500 (SPY) | +14.9% | +80.3% |
| Per year | +68.3% | -48.9% |
| Volatility (annualized) | 114.8% | 224.8% |
| Max drawdown | -78.2% (Oct 2025→Feb 2026) | -98.0% (Jan 2023→Dec 2024) |
ASST revenue by business segment (quarter ended Jun 30, 2026)
| Line | Revenue | Share of total | YoY |
|---|---|---|---|
| Asset Management | $1.5M | 51.4% | +1.6% |
| Medical Device | $1.4M | 47.2% | — |
| Corporate & Other | $41,000 | 1.4% | +78.3% |
| Total revenue | $2.9M | 100% | — |
ASST revenue by product line (quarter ended Jun 30, 2026)
| Line | Revenue | Share of total | YoY |
|---|---|---|---|
| Investment advisory fees | $1.5M | 51.4% | +1.6% |
| Medical device revenues | $1.4M | 47.2% | — |
| Other revenue | $41,000 | 1.4% | +78.3% |
| Total revenue | $2.9M | 100% | — |
As tagged by the company in its SEC 10-Q / 10-K filings (XBRL).
ASST suppliers, customers and competitors (named in its 10-K)
| Relationship | Company | Sentence in the filing |
|---|---|---|
| Partner | Strategy Inc (MSTR) | “Upon receiving an incident report, Corporate Strategy and our MSP perform an initial assessment to determine severity level, whether escalation to executive leadership is needed, and whether cyber insurance notification and approved partner engagement is required.” |
| Partner | Federal Deposit Insurance | “Further, bitcoin held with our future custodians or transacted with its trade execution partners will not be subject to the same protections as are available to cash or securities deposited with or transacted by institutions subject to regulation by the Federal Deposit Insurance Corporation or the Securities Investor Protection Corporation.” |
| Partner | Securities Investor Protection | “Further, bitcoin held with our future custodians or transacted with its trade execution partners will not be subject to the same protections as are available to cash or securities deposited with or transacted by institutions subject to regulation by the Federal Deposit Insurance Corporation or the Securities Investor Protection Corporation.” |
| Partner | Barclays Capital | “•On November 5, 2025, the Company entered into an underwriting agreement with Barclays Capital Inc. and Cantor Fitzgerald & Co., as the joint book-running managers and representatives of the several underwriters, relating to the issuance and sale in an underwritten offering registered under the Securities Act of 2,000,000 shares of our SATA Stock, at a public offering price of $80.00 per share (the "SATA IPO").” |
Quoted from the company's 10-K filed Mar 19, 2026.
ASST company outlook (results filed Aug 10, 2026)
- “Examples of forward-looking statements include, but are not limited to, express or implied statements regarding the outlook and expectations of Strive and its subsidiaries, 7 the strategic benefits and financial benefits of the merger transaction with Semler Scientific, Inc.”
Quoted word-for-word from the SEC 8-K results press release.
ASST analyst estimates and revisions
| Period | EPS estimate | 90 days ago | Change | Revenue estimate | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends Sep 2026) | $-0.21 | $-0.24 | -12.2% | $3.1M | 2 |
| Next quarter (ends Dec 2026) | $-0.22 | $-0.22 | +0.0% | $3.1M | 2 |
| Current fiscal year (ends Dec 2026) | $-5.46 | $-4.06 | +34.5% | $11.9M | 2 |
| Next fiscal year (ends Dec 2027) | $-0.96 | $-1.04 | -8.1% | $11.3M | 2 |
ASST options: expected move
Options price a move of about ±19.0% (±$5.52) by Nov 13, 2026, which includes earnings on Nov 10, 2026; the earnings reaction alone is priced at about ±4.5%. Over the last 7 reports the stock moved ±6.4% on average.
| Expiration | Days | ATM implied volatility | Expected move |
|---|---|---|---|
| Oct 30, 2026 | 7 | 99.9% | ±11.9% |
| Nov 6, 2026 | 14 | 96.8% | ±15.7% |
| Nov 13, 2026 | 21 | 96.9% | ±19.0% |
| Nov 20, 2026 | 28 | 102.0% | ±22.8% |
| Nov 27, 2026 | 35 | 96.8% | ±24.0% |
| Dec 4, 2026 | 42 | 98.4% | ±26.7% |
| Dec 18, 2026 | 56 | 91.2% | ±28.5% |
| Jan 15, 2027 | 84 | 92.3% | ±35.2% |
30-day implied volatility 98.3% vs 73.3% realized over the last 30 trading days. Put/call ratio (volume) 0.57. Cboe delayed quotes (15 min). Expected move = at-the-money straddle.
Key Statistics (as of October 23, 2026 at 09:16 UTC)
| Price | USD 29.03 |
|---|---|
| Change | ▼ 5.59% (down) |
| Previous Close | USD 30.75 |
| Open | USD 29.22 |
| Day Range | USD 27.96 – 29.77 |
| 52-Week Range | USD 7.02 – 36.2 |
| Volume | 7,787,951 shares |
| Market Cap | $2.93B |
| Exchange | NGM |
Technical Analysis (ASST)
Nexqual's technical model rates ASST "STRONG BUY" based on 5 bullish and 0 bearish signals across 127 daily candles, as of October 23, 2026 at 09:16 UTC.
| Overall Signal | STRONG BUY |
|---|---|
| RSI (14) | 54.65 (neutral) |
| vs SMA50 | Above (USD 25.34) |
| MACD | 0.44 (positive) |
Analyst Ratings (ASST)
Wall Street analysts rate ASST "Buy" based on 5 analysts, with a mean price target of USD 38.8 (range USD 32–56), per Nexqual as of October 23, 2026 at 09:16 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 5 |
| Mean Target | USD 38.8 |
| High Target | USD 56 |
| Low Target | USD 32 |
| Buy / Hold / Sell | 5 / 0 / 0 |
Earnings (ASST)
| Next Earnings Date | 2026-11-10 |
|---|---|
| EPS Estimate | USD -0.22 |
| Revenue Estimate | $3.05M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD -3.65 vs est -0.25 ▼ miss |
| 2026-03-31 | USD -5.19 vs est -2.4 ▼ miss |
Source: Nexqual, October 23, 2026 at 09:16 UTC.
Financials & Fundamentals (ASST)
| Total Revenue | $8.50M |
|---|---|
| Revenue Growth (latest quarter, YoY) | +94.60% |
| Gross Margin | +0.00% |
| Operating Margin | -8483.03% |
| Profit Margin | +0.00% |
| ROE | -137.06% |
| Debt / Equity | 0 |
| Current Ratio | 7.62 |
| Total Cash | $188.32M |
| Total Debt | $3.32M |
Source: Nexqual, October 23, 2026 at 09:16 UTC.
Financial Health Score (ASST)
Nexqual rates Strive, Inc.'s overall financial health "Mixed" across five dimensions, as of October 23, 2026 at 09:16 UTC.
| Growth | Strong — Revenue +95% YoY (latest Q) |
|---|---|
| Profitability | Critical — Net margin -7410% (last 12 months); banks have no gross margin |
| Balance Sheet | N/A — Not comparable for banks: deposits and customer funds sit on the balance sheet, so cash vs debt does not measure safety (SEC industry: Finance Services) |
| Cash Flow | N/A — Not meaningful for banks and lenders: lending and trading move operating cash flow by billions each year (SEC industry: Finance Services) |
| Efficiency | Critical — ROE -137%, ROA -72.1% |
Ownership (ASST)
| Insider Ownership | +1.08% |
|---|---|
| Institutional Ownership | +39.67% |
| Shares Outstanding | 91.71M |
| Float | 74.61M |
| Short % of Float | +25.03% |
Source: Nexqual, October 23, 2026 at 09:16 UTC.
Leadership (ASST)
Strive, Inc. is led by Matthew Ryan Cole C.F.A., Chairman & CEO, per Nexqual as of October 23, 2026 at 09:16 UTC.
| Chairman & CEO | Matthew Ryan Cole C.F.A. |
|---|---|
| CFO & Director | Benjamin Bartley Pham |
| Chief Legal Officer & Director | Brian Logan Beirne |
| Chief Strategy Officer & Board Observer | Avik Roy |
| Chief Marketing Officer & Director | Arshia Sarkhani |
Major Backers & Investors (ASST)
Notable institutional backers of Strive, Inc. include FMR, LLC, Fidelity, Capital International Investors, according to Nexqual as of October 23, 2026 at 09:16 UTC.
Active Investors
| Investor | Stake |
|---|---|
| FMR, LLC | 13.07% |
| Fidelity | 7.18% |
| Capital International Investors | 3.99% |
| SmallCap World Fund Inc | 3.88% |
| Goldman Sachs | 2.76% |
| Morgan Stanley | 1.88% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 6.96% |
| Vanguard Group | 3.63% |
| Geode Capital | 2.43% |
| State Street | 1.99% |
Source: Nexqual, October 23, 2026 at 09:16 UTC.
From Strive, Inc.'s Latest SEC 10-K Filing (filed 2026-03-19)
Key Strengths & Strategy (as disclosed to the SEC)
- Our subsidiary, Semler Scientific, currently markets a patented and FDA-cleared, vascular testing product, QuantaFlo.
- Semler Scientific previously reported that it is experiencing and expects to continue to experience decreased usage of its QuantaFlo device due various factors, including the 2024 Medicare Advantage and Part D Final Rate Announcement issued by the Centers for Medicare and Medicaid Services ("CMS").
- Executive Branch, Congress and a number of U.S. federal and state agencies, including the Financial Crimes Enforcement Network, the Commodity Futures Trading Commission ("CFTC"), the U.S.
- A blood flow waveform is instantaneously constructed by our proprietary software algorithm.
Partnerships
- Semler Scientific has been cooperating with civil investigative demands from DOJ (as defined below) since 2017 related to claims for reimbursement related to Semler Scientific's QuantaFlo device and entered into a settlement agreement with DOJ related thereto in September 2025.
- Relative to a traditional depreciating fiat-denominated benchmark, implementing a bitcoin hurdle rate establishes a higher level of accountability and strategic investment discipline, since our decisions are measured against an asset we believe will appreciate over time.
Legal & Regulatory Risks (Item 1A, quoted)
- Our vascular testing product and any future medical devices that we may develop or services that we may offer are subject to extensive regulation in the United States by the federal government, including by the FDA.
- The FDA may change its policies, adopt additional regulations, or revise existing regulations, in particular relating to the 510(k) clearance process.
- The FDA and other regulatory agencies strictly regulate the promotional claims that may be made about medical devices.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| BXSL | Blackstone Secured Lending Fund | USD 23.91 | ▲ 2.31% |
| VCTR | Victory Capital Holdings, Inc. | USD 107.39 | ▼ 0.2% |
| PDI | PIMCO Dynamic Income Fund | USD 14.3 | ▲ 1.2% |
| AMG | Affiliated Managers Group, Inc. | USD 395.53 | ▲ 0.48% |
| IVZ | Invesco Ltd | USD 28.79 | ▼ 1.57% |
| SEIC | SEI Investments Company | USD 104.5 | ▼ 3.62% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 23, 2026 at 09:16 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt